AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma
Phase 3positiveetentamigPositive
AI Analysis
Summary
AbbVie announced positive Phase 3 CERVINO trial results for etentamig, a BCMA x CD3 bispecific T-cell engager, demonstrating significant improvements in response rate and progression-free survival in relapsed/refractory multiple myeloma patients compared to standard therapy.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Etentamig significantly improved response rate and progression-free survival versus standard available therapy
Importance:8/10
Sentiment:
0.85
Phase 3positive resultsmultiple myelomabispecificBCMACD3T-cell engager
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on September 3, 2026 8:09 PM